If ION-3 study will show that for some patients 8-weeks therapy is enough, then yes I think GILD will seek 8-week labeling. It can give then another angle for marketing.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.